Generation Bio Co reports results for the quarter ended September 30 - Earnings Summary

Generation Bio Co reported an adjusted loss of 82 cents per share for the quarter ended September 30, an improvement from a loss of $2.30 per share a year ago. Revenue fell 78.9% to $1.59 million, below analyst expectations of $660,000. The company incurred a quarterly loss of $5.52 million, with shares down 14.2% this quarter and 50.5% year-to-date. Analysts maintain a "buy" rating, with a median 12-month price target of $13.50, indicating a potential upside of 61.1% from the last closing price of $5.25.

Generation Bio | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 1.594 M

Generation Bio | 8-K: FY2025 Q3 Revenue Beats Estimate at USD 1.594 M

Generation Bio Co. reports third quarter net loss of $5.5 million

Generation Bio Co. reported a net loss of $5.5 million for Q3 2025, an improvement from a $15.3 million loss in Q3 2024. The company's cash position decreased to $89.6 million from $185.2 million at the end of 2024. R&D expenses rose to $21.7 million, while general and administrative expenses increased to $12.2 million. Additionally, the company settled litigation with its landlord, resulting in a $25.5 million gain on lease termination.

Generation Bio Co expected to post a loss of $3.17 a share - Earnings Preview

Generation Bio Co is projected to report a loss of $3.17 per share and a significant 91.3% drop in quarterly revenue to $660,000 for the period ending September 30, 2025. The average analyst rating remains "buy" with a median 12-month price target of $13.50, reflecting a potential upside of 59.3% from the last closing price of $5.50. Previous earnings reports show mixed results, with several misses and a few beats in the last quarters.